|
Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
2/2007
vol. 109 abstract:
Original paper
Intravitreal bevacizumab (Avastin) iniections for neovascular age-related macular degeneration (AMD) – preliminary results
Jerzy Mackiewicz
1
,
Anna Mańkowska
1
,
Joanna Dolar-Szczasny
1
,
Anna Zubilewicz
1
,
Agnieszka Oleszczuk
1
,
Katarzyna Nowomiejska
1
,
Robert Rejdak
1
,
Zbigniew Zagórski
1
Klinika Oczna 2007, 109 (2): 146-149
Online publish date: 2007/06/12
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Purpose
To evaluate effects of intravitreal bevacizumab on visual acuity and angiographic lesions characteristics in patients with neovascular AMD and to report safety of such treatement. Material and methods 32 patients with confirmed choroidal neovascularisation (CNV) and AMD were treated. Patients received 2 intravitreal bevacizumabu (1.25 mg) iniections on 1-3 months basis. Control ophthalmic evaluations included visual acuity measurements with EDTRS charts, intraocular pressure measurements, complete ophthalmic examination in slit lamp, fluorescein angiography and blond pressure measurements. Results In 18 patients (56%) visual acuity improvement at a mean 3 lines on EDTRS charts was observed, in 9 patients (28%) visual acuity did not change and in 5 (16%) cases decreased visual acuity (about 1,5 lines in EDTRS charts) was noted. Mean follow-up period was 3 months after second injection. In most study eyes fluorescein angiography revealed a marked reduction in leakage from CNV. Apart from one case with endophthalmitis symptoms after second bevacizumab injection, we did not observed systemic or ocular adverse effects of the applied treatment. Conclusions Short-term results suggest that intravitreal bevacizumab is relatively safe form of AMD treatement and is associated with improvement in visual acuity and reduction in angiographic leakage in most patients with neovascular AMD. Further evaluation of the long-term effectiveness of this treatment is warranted. keywords:
vascular endothelial growth factor (VEGF), choroidal neovascularisation (CNV), age-related macular degeneration (AMD), bevacizumab |
|
POLSKI
